Resolution on the results of the expert council on approaches to diagnostics and therapy of RET-positive non-small cell lung cancer in the Russian Federation

1. The state of cancer care for the population of Russia in 2023. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024.262 p. (In Russ.)

2. Malignant tumors in Russia in 2023 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024.276 p. (In Russ.)

3. Lung cancer. Eds.: K.K. Laktionov, V.V. Breder — М. : “GRANAT”, 2020 (In Russ.)

4. Laktionov K.K., Artamonova E.V., Breder V.V., et al. Non-small cell lung cancer. Practical recommendations RUSSCO, part 1.1. Zlokachestvennie opuholi = Malignant Tumors 2024;14(3s2):65–104 (In Russ.). doi: 10.18027/2224-5057-2024-14-3s2-1.1-04 (In Russ.)

5. Latysheva N.S., Babu M.M. Discovering and understanding oncogenic gene fusions through data intensive computational approaches. Nucleic Acids Res 2016;44(10):4487–503. doi: 10.1093/nar/gkw282

6. Subbiah V., Cote G.J. Advances in targeting RET-dependent cancers. Cancer Discov 2020;10(4):498–505. doi: 10.1158/2159-8290.CD-19-1116

7. Agrawal N., Jiao Y., Sausen M., et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013;98(2):E364–9. doi: 10.1210/jc.2012-2703

8. Al-Jundi M., Thakur Sh., Gubbi S., Klubo-Gwiezdzinska J. Novel targeted therapies for metastatic thyroid cancer-a comprehensive review. Cancers (Basel) 2020;12(8):2104. doi: 10.3390/cancers12082104

9. Gautschi O., Milia J., Filleron T., et al. Targeting RET in patients with RET-Rearranged lung cancers: results from the global, multicenter RET registry. J Clin Oncol 2017;35(13):1403–1410. doi: 10.1200/JCO.2016.70.9352

10. Li T., Kung H.J., Mack P.C., Gandara D.R. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013;31(8):1039–49. doi: 10.1200/JCO.2012.45.3753

11. Results of the ANO NOOPS project "Targeted Sequencing of Tumor Tissue in Patients with Non-Small Cell Non-Squamous Lung Cancer in the Russian Federation". Available at: https://77.37.209.172/archive/?id=NKZvNa502x0 (In Russ.)

12. Drilon A., Subbiah V., Gautschi O., et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol 2023;41(2):385–394. doi: 10.1200/JCO.22.00393. Erratum in: J Clin Oncol 2023 Nov 1;41(31):4941. doi: 10.1200/JCO.23.01849

13. Subbiah V., Gainor J.F., Oxnard G.R., et al. Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial. Clin Cancer Res 2021;27(15):4160–4167. doi: 10.1158/1078-0432.CCR-21-0800

14. ClinicalTrials.gov identifier NCT04194944. A Study of Selpercatinib (LY3527723) in Participants with Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431). US Clinical Trials Registry, 2025. Available at: https://ichgcp.net/clinical-trials-registry/NCT04194944

15. Zhou C., Solomon B., Loong H.H., et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med 2023;389(20):1839–1850. doi: 10.1056/NEJMoa2309457

16. Loong H.H.F., Goto K., Solomon B.J., et al. Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC. ESMO Congress 2023, LBA4

17. Lee A.T.M., Ou S.I. LIBRETTO-431: Confirming the superiority of selpercatinib to chemotherapy and the lack of efficacy of immune checkpoint inhibitors in advanced RET fusion-positive (RET +) NSCLC, another unique never-smoker predominant molecular subtype of NSCLC. Lung Cancer (Auckl) 2024;15:75–80. doi: 10.2147/LCTT.S460147

18. Soria J.C., Ohe Y., Vansteenkiste J., et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378(2):113–125. doi: 10.1056/NEJMoa1713137

19. Mok T., Camidge D.R., Gadgeel S.M., et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 2020;31(8):1056–1064. doi: 10.1016/j.annonc.2020.04.478

20. Camidge D.R., Bang Y.J., Kwak E.L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13(10):1011–9. doi: 10.1016/S1470-2045(12)70344-3.